Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SRPT vs ACAD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRPT Captures Overall Composite Edge (37.8 SELL vs 42.0 HOLD), While ACAD Leads 4–2 on Growth & Valuation Pillars

SRPT Overall Winner 6-Pillar Tally: SRPT 2 – 4 ACAD Matrix Metrics: SRPT 2 – 8 ACAD

As of Nov 16, 2026, Sarepta Therapeutics,, Inc. (SRPT) captures the overall head-to-head institutional edge over Acadia Pharmaceuticals Inc. (ACAD) on higher Unified Composite conviction (37.8/100 SELL vs. 42.0/100 HOLD) after splitting the core matrix 2–8 (led by Valuation Multiples, Options & Positioning), while ACAD wins 4–2 across the 6-pillar growth and valuation breakdown. SRPT trades at $15.25 (10.8x Forward P/E, -0.4% operating margin) versus ACAD at $18.91 (17.8x Forward P/E, 10.2% operating margin).

  • Composite vs. Pillar Nuance: While ACAD currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. SRPT 37.8/100 SELL), SRPT captures the overall institutional head-to-head verdict (2–8 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-0.4% vs. 10.2% operating margin) and revenue trajectory (-4.5% vs. +22.8% YoY).
  • Technical & Structure Timing Caution: SRPT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.0); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRPT vs ACAD
SRPT NASDAQ Head-to-Head Winner
Sarepta Therapeutics,, Inc. Common Stock
Pharmaceutical Preparations
$15.25
-5.1% 1D
Market Cap $1.7B
TTM Revenue $1.96B
Forward P/E 10.8x
Beta / 30D Vol 1.48β · 59% Vol
Unified Composite Score
37.8 / 100 SELL
Tech 32.0 Fund 51.0 Flow 71.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.9%), weak momentum, RSI 33
RSI-14: 33.0 · SMA20: $17.82 · SMA50: $18.44
ACAD NASDAQ
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$18.91
+0.88% 1D
Market Cap $3.1B
TTM Revenue $1.20B
Forward P/E 17.8x
Beta / 30D Vol 0.12β · 93% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 43.0 Fund 52.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.8%), weak momentum, RSI 44
RSI-14: 44.0 · SMA20: $19.82 · SMA50: $21.61

6-Pillar Scorecard Institutional Category Breakdown (SRPT 2 – 4 ACAD)

Columns: Metric · SRPT · ACAD
1. Valuation Multiples SRPT
Forward P/E 10.8x 17.8x
Trailing P/E N/M 8.6x
PEG Ratio N/M N/M
EV / Revenue 1.2x 2.4x
2. Growth & Scale ACAD
Revenue Growth (YoY) -4.5% +22.8%
Earnings Growth (YoY) N/A -26.2%
TTM Revenue (USD) $1.96B $1.20B
Market Cap $1.7B $3.1B
3. Profitability & Quality ACAD
Gross Margin 23.4% 63.9%
Operating Margin -0.4% 10.2%
Net Profit Margin -5.9% 30.1%
Return on Equity (ROE) -8.1% 31.4%
4. Balance Sheet & Cash Flow ACAD
Cash Generation (TTM) $172M $181M
Cash Flow Margin 8.8% 15.0%
Net Cash / Leverage $580M Net Debt (0.69x D/E) $251M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRPT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 54.5% (7th %ile) 42.6% (4th %ile)
Put/Call OI Skew 0.66x (Call-Skewed) 0.33x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ACAD
OpEx & R&D Intensity 23.8% of Rev ($466M) 53.7% of Rev ($646M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRPT (2) vs ACAD (8)
Institutional Metric SRPT ACAD Criterion Row Edge
Market Capitalization
Scale
$1.7B $3.1B Larger Scale ACAD
Trailing P/E Ratio
Valuation
N/M 8.6x Lower Multiple ACAD
Forward P/E Ratio
Valuation
10.8x 17.8x Lower Multiple SRPT
Revenue Growth (YoY)
Growth
-4.5% +22.8% Higher Growth ACAD
Operating Margin (TTM)
Profitability
-0.4% 10.2% Higher Margin ACAD
Net Profit Margin
Profitability
-5.9% 30.1% Higher Margin ACAD
Return on Equity (ROE)
Capital Efficiency
-8.1% 31.4% Higher ROE ACAD
52-Week Range Position
Momentum
6% ($15–$25) 20% ($16–$31) Stronger Trend ACAD
Beta / 30D Volatility
Risk Regime
1.48β · 59% Vol 0.12β · 93% Vol Lower Realized Risk SRPT
Unified Institutional Score
Composite Signal
37.8 / 100 (SELL) 42.0 / 100 (HOLD) Higher Composite ACAD
Trailing 12M Revenue (USD)
Operating Scale
$1.96B $1.20B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.4% 63.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.2x EV/Rev N/M PEG · 2.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$172M ($580M Net Debt (0.69x D/E)) $181M ($251M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACAD +9.75 pp
SRPT: -10.82% · ACAD: -1.07%
3M Horizon SRPT +21.96 pp
SRPT: -15.37% · ACAD: -37.33%
6M Horizon ACAD +1.77 pp
SRPT: -10.35% · ACAD: -8.58%
1Y Horizon SRPT +5.57 pp
SRPT: -14.42% · ACAD: -19.99%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRPT Revenue ACAD Revenue SRPT Op. Margin ACAD Op. Margin Margin Leader
FY2018 $300M $220M -114.1% -110.6% ACAD
FY2019 $380M $340M -185.3% -72.7% ACAD
FY2020 $460M $440M -123.8% -64.9% ACAD
FY2021 $610M $480M -75.1% -35.2% ACAD
FY2022 $840M $520M -63.5% -43.2% ACAD
FY2023 $1.14B $730M -23.4% -10.1% ACAD
FY2024 $1.79B $960M 12.2% 24.1% ACAD
FY2025 $1.86B $1.07B -37.5% 9.8% ACAD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRPT BREAKDOWN
52d in phase · OBV DISTRIBUTION
Current IV 54.5%
IV Percentile 7th %ile
Put/Call OI Skew 0.66x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SRPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACAD BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 42.6%
IV Percentile 4th %ile
Put/Call OI Skew 0.33x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ACAD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -0.4% operating margin.
OpEx & R&D Reinvestment 23.8% of Rev ($466M)
90D Engineering Disclosures 0 Published
ACAD Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $3.1B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 53.7% of Rev ($646M)
90D Engineering Disclosures 0 Published

Investor FAQ SRPT vs ACAD Key Questions & Quantitative Answers

As of Nov 16, 2026, Sarepta Therapeutics,, Inc. (SRPT) captures the overall head-to-head institutional edge over Acadia Pharmaceuticals Inc. (ACAD) on higher Unified Composite conviction (37.8/100 SELL vs. 42.0/100 HOLD) after splitting the core matrix 2–8 (led by Valuation Multiples, Options & Positioning), while ACAD wins 4–2 across the 6-pillar growth and valuation breakdown. SRPT trades at $15.25 (10.8x Forward P/E, -0.4% operating margin) versus ACAD at $18.91 (17.8x Forward P/E, 10.2% operating margin). Composite vs. Pillar Nuance: While ACAD currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. SRPT 37.8/100 SELL), SRPT captures the overall institutional head-to-head verdict (2–8 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-0.4% vs. 10.2% operating margin) and revenue trajectory (-4.5% vs. +22.8% YoY). Technical & Structure Timing Caution: SRPT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.0); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACAD leads the Growth & Scale pillar: SRPT posts -4.5% YoY revenue growth and N/A YoY earnings growth on $1.96B TTM revenue (23.4% gross margin, -0.4% operating margin), compared with ACAD at +22.8% YoY revenue growth and -26.2% YoY earnings growth on $1.20B TTM revenue (63.9% gross margin, 10.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SRPT cumulative revenue shifted +520.0% while ACAD shifted +386.4%. In operating R&D and SG&A reinvestment, SRPT deploys 23.8% of Rev ($466M) (0 90-day corporate R&D disclosures) versus 53.7% of Rev ($646M) (0 disclosures) for ACAD.

SRPT screens cheaper on headline valuation multiples. SRPT trades at 10.8x Forward P/E, N/M Trailing P/E, N/M PEG, and 1.2x EV/Revenue (8.8% FCF margin), whereas ACAD trades at 17.8x Forward P/E, 8.6x Trailing P/E, N/M PEG, and 2.4x EV/Revenue (15.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRPT (-8.1% ROE) versus ACAD (31.4% ROE) capital efficiency.

In options market volatility and institutional positioning, SRPT carries 54.5% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.48β · 59% Vol realized risk). By comparison, ACAD carries 42.6% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.33x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.12β · 93% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.